Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are presently covering the company, Marketbeat reports. Five research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $37.00.

Several research analysts have recently issued reports on LKFT shares. TD Cowen assumed coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Friday, August 21st. They issued a “buy” rating for the company. UBS Group raised Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a report on Wednesday, September 23rd. Weiss Ratings upgraded Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday. Royal Bank Of Canada raised Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and increased their price target for the company from $26.00 to $45.00 in a research note on Wednesday, September 23rd. Finally, Morgan Stanley lowered their price target on Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 11th.

Lakefront Biotherapeutics American Depositary Shares Price Performance

Shares of Lakefront Biotherapeutics American Depositary Shares stock opened at $29.32 on Wednesday. The business’s fifty day moving average price is $28.37 and its two-hundred day moving average price is $28.68. The company has a market capitalization of $1.93 billion, a P/E ratio of -20.79 and a beta of 0.24. Lakefront Biotherapeutics American Depositary Shares has a 1-year low of $25.68 and a 1-year high of $36.24.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its quarterly earnings results on Monday, August 10th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $1.00. The business had revenue of $15.47 million for the quarter, compared to analyst estimates of $7.29 million. On average, research analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -1.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

Several hedge funds have recently made changes to their positions in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Lakefront Biotherapeutics American Depositary Shares during the first quarter valued at approximately $248,000. ABC Arbitrage SA acquired a new position in Lakefront Biotherapeutics American Depositary Shares in the first quarter worth approximately $382,000. QRG Capital Management Inc. increased its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 21.9% in the first quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock valued at $591,000 after buying an additional 3,535 shares in the last quarter. Finally, Madison Avenue Partners LP increased its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 0.8% in the fourth quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock valued at $72,371,000 after buying an additional 17,394 shares in the last quarter. Institutional investors and hedge funds own 32.46% of the company’s stock.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.